Symbiotec Pharmalab Ltd. is a research-driven pharmaceutical and biotechnology company focused on APIs, corticosteroid and steroidal-hormone products, CDMO services, and complex injectables.
With over 30 years of experience, Symbiotec has evolved into a backward-integrated pharmaceutical platform with capabilities in fermentation, biosynthesis, biotransformation, and chemical synthesis, supported by global regulatory approvals.
The company has a portfolio of 60+ corticosteroid and steroidal-hormone APIs, including Hydrocortisone, Betamethasone, Methylprednisolone, Progesterone, Estrogen, and Testosterone, supplied to global markets.
Symbiotec operates across three business verticals: API Products, CDMO Services, and Complex Injectables, including double-chamber injectable technologies.
The company follows a “farm/microbe-to-pharmacy” model, using fermentation and in-house manufacturing of key starting materials to reduce dependence on external suppliers.
As of March 31, 2026, Symbiotec had manufacturing facilities in Rau, Pithampur, Ujjain and Mhow, with 584.67 MT chemical synthesis and 700 KL fermentation capacity, plus capacity for 20 million complex injectable vials annually.
Symbiotec serves 200+ customers across 40+ countries, with international markets contributing 67.04% of revenue from operations in Fiscal 2026.
Symbiotec Pharmalab IPO – Details
| IPO Opening Date | 24 August 2026 |
| IPO Closing Date | 27 August 2026 |
| Issue Type | Book Built Issue IPO |
| Issue Size | Total Issue Size: 1,77,86,442 Shares Worth ₹1757 Crore Fresh Issue: 15,21,261 Shares Worth ₹150.00 Crore Offer For Sale: 1,62,65,181 Shares Worth ₹1607.00 Crore |
| Face Value | ₹2 per equity share |
| IPO Price | ₹933 – ₹988 per share |
| Market Lot | 15 Shares |
| Min Order | 15 Shares [1 Lot] |
| Employee Discount | ₹90 |
| Listing At | BSE, NSE |
| Register | MUFG Intime India Private Limited |
| QIB Shares Offered | 50% |
| NII (HNI) Shares Offered | 15% |
| Retail Shares Offered | 35% |
Symbiotec Pharmalab IPO – Date Schedule
| IPO Open Date | 24 August 2026 |
| IPO Close Date | 27 August 2026 |
| Basis of Allotment | 28 August 2026 |
| Initiation of Refund | 31 August 2026 |
| Credit of Shares to Demat Account | 31 August 2026 |
| IPO Listing Date | 01 September 2026 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 27, 2026 |
Symbiotec Pharmalab IPO – Lots Size & Price
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1020 | ₹10,07,760 |
Competitive Strength
- Global leadership in corticosteroid and steroidal-hormone APIs.
- Long-standing relationships with domestic and global customer base.
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record.
- Continuous investment in R&D, with leading technological capabilities among Indian peers.
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings.
Company Promoters
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP.
Company Financials
| Particulars | Total Revenue | Total Expense | Profit After Tax | Total Borrowing |
|---|---|---|---|---|
| 31 March 2024 | ₹723.33 Cr | ₹590.99 Cr | ₹100.06 Cr | ₹247.21 Cr |
| 31 March 2025 | ₹755.98 Cr | ₹608.85 Cr | ₹96.79 Cr | ₹540.92 Cr |
| 31 March 2026 | ₹872.26 Cr | ₹709.90 Cr | ₹109.90 Cr | ₹387.91 Cr |
Key Performance Indicator
| KPI | Values (Mar 31, 2026) |
|---|---|
| ROE | 11.19% |
| ROCE | 11.56% |
| RoNW | 9.48% |
| Debt/Equity | 0.33% |
| PAT Margin | 12.60% |
| EBITDA Margin | 26.59% |
| NAV | 184.69 |
| Pre IPO | Post IPO | |
| EPS (₹) | 19.10 | 19.00 |
| P/E (x) | – | – |
Object Of The Issue
| Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company. | ₹112.50 |
| General corporate purposes. |
Symbiotec Pharmalab IPO Peer Comparison
| S. No. | Face Value (₹) | Company Name | P/E Ratio |
|---|---|---|---|
| 1 | 1 | Concord Biotech Limited | 61.07 |
| 2 | 2 | Divi’s Laboratories Limited | 87.80 |
| 3 | 1 | Cohance Lifesciences Limited | 95.02 |
| 4 | 2 | Laurus Labs Limited | 109.36 |
✅Strengths
- Strong 60+ API portfolio across key therapeutic segments.
- Serves 200+ customers across 40+ countries.
- Backward-integrated manufacturing with global regulatory approvals.
- Expanding into CDMO services and complex injectables.
- Strong financial growth with improving profitability.
⚠️Risks
- High dependence on API products and key APIs.
- Regulatory and quality compliance risks.
- High dependence on international markets and exports.
- Revenue concentration among major customers.
- Manufacturing facilities concentrated in Madhya Pradesh.
Symbiotec Pharmalab IPO Promoter Holding
| Pre Issue Share Holding | 36.41% |
| Post Issue Share Holding | 33.28% |
Symbiotec Pharmalab IPO Prospectus
Company Contact Information
| Symbiotec Pharmalab Ltd. 385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331 Phone: +91 731 667 6405 Email: secretarial@symbiotec.com Website: https://www.symbiotec.com/ |
Symbiotec Pharmalab IPO Registrar
| MUFG Intime India Pvt. Ltd. Phone: 022-49186000 Email: symbiotecpharmalab.ipo@in.mpms.mufg.com Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html |
Symbiotec Pharmalab IPO Lead Manager(s)
| 1. JM Financial Limited 2. Avendus Capital Private Limited 3. Motilal Oswal Investment Advisors Limited 4. Nomura Financial Advisory and Securities (India) Private Limited |
Symbiotec Pharmalab IPO FAQs
| What is the Symbiotec Pharmalab IPO? Symbiotec Pharmalab IPO is a main-board IPO. The issue is priced at ₹938 to ₹988 per equity share. The IPO is to be listed on the BSE & NSE. |
| When will the Symbiotec Pharmalab IPO open? The IPO is to open on 24 August 2026 for QIB, NII, and Retail Investors. |
| What is Symbiotec Pharmalab IPO Investors Portion? The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%. |
| What is the Symbiotec Pharmalab IPO Size? Symbiotec Pharmalab IPO size is ₹1,757 Crore. |
| What are the Symbiotec Pharmalab IPO Minimum and maximum lot sizes for Retail? The minimum bid is 15 Shares with ₹14,820, while the maximum bid is 195 Shares with ₹1,92,660. |
| What is the Symbiotec Pharmalab IPO Allotment Date? Symbiotec Pharmalab IPO allotment date is 28 August 2026. |
| What is the Symbiotec Pharmalab IPO Listing Date? Symbiotec Pharmalab IPO listing date is 01 September 2026. The IPO is to be listed on the BSE and the NSE. |
